Frontiers in Immunology's AI Policy: Publisher Rules for the IUIS-Backed Journal
Frontiers in Immunology follows the Frontiers publisher-wide AI policy requiring disclosure, prohibiting AI authorship, and banning AI-generated images across all 200+ Frontiers journals.
Senior Researcher, Oncology & Cell Biology
Author context
Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Frontiers in Immunology is a contradiction that works. It's the official journal of the International Union of Immunological Societies (IUIS), backed by one of the most respected organizations in immunology. It's also a Frontiers journal, part of a publisher that Finland downgraded, that pressured Beall's list into extinction, and that has faced ongoing questions about editorial rigor. The AI policy comes from Frontiers the publisher, not from the IUIS. Understanding which entity sets the rules helps you comply correctly.
The Frontiers AI policy
Frontiers in Immunology follows the Frontiers publisher-wide AI policy. The same rules apply across all 200+ Frontiers journals:
- AI can't be an author. Generative AI tools don't meet Frontiers' authorship criteria. They can't take accountability, approve manuscripts, or make intellectual contributions.
- AI use must be disclosed. If you used generative AI tools during manuscript preparation, disclose this in the manuscript. Frontiers has designated a disclosure section in the manuscript template.
- AI-generated images are prohibited. No figures or visual content from generative AI tools. Data-derived visualizations from real experiments are fine.
- Authors are responsible for all content. Every co-author must verify the accuracy and integrity of the published work, including AI-assisted sections.
- The policy covers all article types. Research articles, reviews, mini-reviews, perspectives, all follow the same rules.
IUIS vs. Frontiers: who controls the AI policy?
This distinction matters because it determines where to look for authoritative guidance:
Aspect | IUIS role | Frontiers role |
|---|---|---|
AI policy text | No separate IUIS AI policy | Frontiers sets the rules |
Editorial oversight | Provides editor-in-chief, editorial board members | Provides publishing platform, staff editors |
Peer review management | Board members serve as editors | Frontiers' interactive review system |
Quality standards | IUIS name implies quality expectations | Frontiers' publisher policies apply |
Policy updates | Consulted but doesn't control | Frontiers decides unilaterally |
The practical implication: if Frontiers updates its AI policy, Frontiers in Immunology follows automatically. The IUIS doesn't have veto power over publisher policies. If you're looking for the authoritative AI policy document, it's on Frontiers' website, not IUIS's.
This creates an unusual situation. Researchers submit to Frontiers in Immunology partly because of the IUIS imprimatur, but the AI rules they must follow are set by a commercial publisher with a different reputation profile. The dissonance doesn't change what you need to do, it just explains why some immunologists are uncomfortable with the arrangement.
The interactive review model and AI
Frontiers uses a distinctive review process that interacts with AI disclosure in interesting ways:
Phase 1: Independent review. Reviewers assess the manuscript independently, typically within 7 days.
Phase 2: Interactive review. Authors and reviewers communicate through Frontiers' online forum. This is where AI-related concerns are discussed directly between parties.
Published reviewer names. When a paper is accepted, reviewer names are published alongside it. Reviewers who reject papers don't get named.
How this affects AI disclosure:
- If a reviewer has concerns about AI-generated text, they raise them during the interactive phase. The author can respond directly, add disclosure, or revise the manuscript. This is more collaborative than the traditional one-way review at most journals.
- The published reviewer names create a soft deterrent: reviewers who approve papers with obvious undisclosed AI use have their names attached to that decision.
- The interactive forum creates a record of AI-related discussions, though this record isn't always publicly visible.
Writing the disclosure for Frontiers in Immunology
Frontiers provides a manuscript template with designated sections. AI disclosure goes in the disclosure section or in Methods:
Standard disclosure:
"During the preparation of this work, the authors used ChatGPT (GPT-4, OpenAI) to improve the language and clarity of the manuscript. The authors reviewed and edited the content as needed and take full responsibility for the content of the publication."
For a paper with computational immunology analysis:
"Single-cell RNA-seq data was analyzed using Seurat v5 and Scanpy v1.9 (see Methods: scRNA-seq Analysis). During manuscript preparation, GitHub Copilot (Microsoft) assisted with writing custom R scripts for the cell type annotation pipeline. ChatGPT (GPT-4, OpenAI) was used to improve the readability of the Discussion. All code was validated against reference datasets. The authors take full responsibility for the published content."
For a review article:
"The authors used ChatGPT (GPT-4, OpenAI) to assist with organizing the literature review structure and to improve the language of the manuscript. The scientific analysis, evaluation of evidence, and conclusions are entirely the work of the authors. All AI-generated suggestions were reviewed and edited as needed."
What requires disclosure at Frontiers in Immunology
Use case | Disclosure required? | Notes |
|---|---|---|
Grammar/spell check | No | Standard tools exempt |
ChatGPT for language editing | Yes | Disclosure section or Methods |
AI for scRNA-seq code | Yes | Specify which steps |
Seurat/Scanpy usage | No (research tool) | Standard Methods |
AI-generated immune cell diagrams | Prohibited | Use BioRender instead |
AI for figure legends | Yes | Part of the manuscript |
AI for review article organization | Yes | Describe AI's role vs. author's analysis |
AI for statistical code | Yes | Confirm validation |
AI for meta-analysis scripts | Yes | Describe scope |
AI for graphical abstract | Prohibited if generative | Standard design tools only |
The Finland JUFO context
Finland's Publication Forum (JUFO) downgraded 78 Frontiers journals to Level 0 in December 2024. Frontiers in Immunology was NOT downgraded, it retained Level 1 status, alongside 21 other Frontiers journals.
This matters for AI policy in two ways:
Institutional scrutiny is higher. Researchers at institutions that use the JUFO system (primarily Finnish universities, but the system influences Scandinavian research evaluation broadly) face additional pressure to demonstrate that their Frontiers publications meet quality standards. Thorough AI disclosure is part of demonstrating that quality.
The publisher's reputation affects perception. Even though Frontiers in Immunology wasn't downgraded, the publisher's broader reputational challenges mean that papers from any Frontiers journal receive more scrutiny from some evaluators. Clean AI compliance is one way to ensure your paper isn't questioned on process grounds.
Consequences of non-disclosure
Frontiers' enforcement process:
During interactive review:
- Reviewer flags concern through the discussion forum
- Author responds directly and can add disclosure
- This back-and-forth is less formal than at traditional journals but can be effective
During editorial assessment:
- Associate editor or handling editor requests disclosure addition
- Papers can be returned for compliance before acceptance
After publication:
- Correction for minor non-disclosure
- Expression of concern for unclear scope
- Retraction for fabricated content or false claims
- Frontiers' integrity team investigates systematic issues
Community dynamics in immunology: Frontiers in Immunology has a large readership, it's one of the highest-volume immunology journals worldwide. An AI disclosure issue at this journal is visible to a broad cross-section of the immunology community, including researchers who publish in Nature Immunology and Immunity. The journal's volume (several thousand articles per year) means many immunologists have published here, and they watch the journal's quality signals closely.
Comparison with other immunology journals
Feature | Frontiers in Immunology | Nature Immunology | Immunity | Journal of Immunology | Journal of Experimental Medicine |
|---|---|---|---|---|---|
Publisher | Frontiers | Springer Nature | Cell Press (Elsevier) | AAI (Oxford UP) | Rockefeller UP |
AI authorship | Prohibited | Prohibited | Prohibited | Prohibited | Prohibited |
Disclosure location | Disclosure section/Methods | Methods | STAR Methods | Methods | Methods |
AI image ban | Yes | Yes | Yes | Yes | Yes |
Review model | Interactive + published names | Confidential | Confidential | Confidential | Confidential |
Impact factor | ~5-7 | ~25-30 | ~25-30 | ~4-5 | ~15 |
Articles/year | ~4,000+ | ~200 | ~200 | ~1,000 | ~300 |
Finland JUFO status | Level 1 (retained) | Level 1 | Level 1 | Level 1 | Level 1 |
Frontiers in Immunology publishes far more articles than any other immunology journal. The volume means it serves a different segment of the immunology community, it's where solid, technically sound immunology research gets published even if it doesn't have the novelty for Nature Immunology or Immunity.
Practical advice for Frontiers in Immunology submissions
For standard research articles:
- Include AI disclosure in the designated section of the Frontiers template
- Be thorough, the interactive review means a reviewer can ask you to expand the disclosure during the discussion phase
- If AI helped with analysis code, mention validation explicitly
For review articles and mini-reviews:
- Frontiers in Immunology publishes many reviews. If AI helped organize the literature or structure the argument, disclose this while making clear that the scientific evaluation is yours.
- Don't use AI to generate conclusions or recommendations in a review, that's the intellectual contribution reviewers and readers expect from the authors.
For special issue submissions:
- Special issues at Frontiers have received scrutiny for quality. Ensure your AI disclosure is impeccable for special issue papers, these are more likely to be evaluated by institutional committees.
- Verify that the guest editor is actively involved and that the review process isn't being handled entirely by Frontiers staff.
Before submission checklist:
- [ ] AI disclosure in designated section or Methods
- [ ] Tool name, version, and use case specified
- [ ] No AI-generated images or graphical abstract
- [ ] Analysis code validated and described
- [ ] All co-authors aware of AI disclosure
- [ ] Disclosure is consistent with Frontiers' current template format
A free manuscript assessment can help verify your Frontiers in Immunology submission meets the journal's requirements.
Sources
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.